Literature DB >> 21683379

Cost-effectiveness of primary prevention strategies for nephrolithiasis.

Yair Lotan1, Margaret S Pearle.   

Abstract

PURPOSE: Stone disease is a highly prevalent condition associated with substantial cost and morbidity. We evaluated the cost-effectiveness of a primary prevention strategy.
MATERIALS AND METHODS: A decision analysis model was constructed to compare the cost of ad hoc management of symptomatic stones vs the cost of primary prevention. A literature search was performed to determine the incidence of stone disease, the effectiveness of nonmedical prevention strategies and cost associated with stone management. One and 2-way sensitivity analyses were performed to determine conditions under which a strategy of primary prevention might be cost-effective.
RESULTS: Assuming a 1% incidence of stones, a 50% risk reduction and a $100 cost per individual per year for primary prevention, the model was used to calculate the overall costs per individual per year without and with a primary prevention strategy of $46 and $123, respectively. One-way sensitivity analyses indicated that primary prevention was cost-effective if the incidence of stones exceeded 4.3% yearly or the cost of prevention was less than $23 per person yearly. Varying other factors (risk reduction, probability of requiring surgery, hours of lost work, emergency room cost) failed to reach cost equivalence under any circumstances or required unrealistic assumptions. Preventive strategies were more costly than no prevention unless the incidence of stone disease was at least 1%, the cost did not exceed $20 per person per year and the prevention strategy was at least 50% effective in preventing stones.
CONCLUSIONS: Primary prevention strategies for stone disease have not been sufficiently evaluated but can theoretically be cost-effective if the population has a sufficiently high incidence of stone disease and the strategy is of low cost and moderately effective.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21683379     DOI: 10.1016/j.juro.2011.03.133

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

Review 1.  Epidemiology of stone disease across the world.

Authors:  Igor Sorokin; Charalampos Mamoulakis; Katsuhito Miyazawa; Allen Rodgers; Jamsheer Talati; Yair Lotan
Journal:  World J Urol       Date:  2017-02-17       Impact factor: 4.226

2.  Paediatrics: A 24 h urine collection is essential in nephrolithiasis evaluation.

Authors:  Boris Chertin
Journal:  Nat Rev Urol       Date:  2014-08-19       Impact factor: 14.432

3.  The economics of stone disease.

Authors:  Noah E Canvasser; Peter Alken; Michael Lipkin; Stephen Y Nakada; Hiren S Sodha; Abdulkadir Tepeler; Yair Lotan
Journal:  World J Urol       Date:  2017-01-20       Impact factor: 4.226

4.  The impact of phone counseling on urinary stone prevention.

Authors:  Amihay Nevo; Karen L Stern; Jonathan P Moore; Mitchell R Humphreys; Mark D Tyson; Mira T Keddis
Journal:  World J Urol       Date:  2020-06-25       Impact factor: 4.226

Review 5.  Metabolic evaluation of urinary lithiasis: what urologists should know and do.

Authors:  Julien Letendre; Jonathan Cloutier; Luca Villa; Luc Valiquette
Journal:  World J Urol       Date:  2014-11-21       Impact factor: 4.226

Review 6.  Economic Considerations in the Management of Nephrolithiasis.

Authors:  Daniel Roberson; Colin Sperling; Ankur Shah; Justin Ziemba
Journal:  Curr Urol Rep       Date:  2020-03-31       Impact factor: 3.092

Review 7.  Recent advances in understanding and managing urolithiasis.

Authors:  Walter L Strohmaier
Journal:  F1000Res       Date:  2016-11-08

Review 8.  Economics of stone disease/treatment.

Authors:  Walter Ludwig Strohmaier
Journal:  Arab J Urol       Date:  2012-03-22

Review 9.  Economic impact of urinary stones.

Authors:  Elias S Hyams; Brian R Matlaga
Journal:  Transl Androl Urol       Date:  2014-09

Review 10.  The preventive treatment of recurrent stone-formation: how can we improve compliance in the treatment of patients with recurrent stone disease?

Authors:  Dirk Jan Kok
Journal:  Urolithiasis       Date:  2015-12-14       Impact factor: 3.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.